Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.
It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This is indicating a positive market growth during the forecast period, 2018–2025.
Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.
Scleritis Market is expected to grow with a healthy CAGR of approximately 6.0% during the forecast period.
Segmentation
scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.
The global market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.
The global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.
The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.
The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Key Players
Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA) Inc. are some of the key players operating in the global scleritis market.
Global Scleritis Market, by Type
- Anterior Scleritis
- Diffuse Scleritis
- Nodular Scleritis
- Necrotizing Scleritis
- Posterior Scleritis
Global Scleritis Market, by Diagnostic Test & Treatment
- Diagnostic Test
- Ultrasonography
- Complete Blood Count
- Biopsy
- Others
- Treatment
- Medication
- Corticosteroid
- Difluprednate
- Prednisolone
- Others
- Nonsteroidal Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- Methotrexate
- Mycophenolate
- Others
- Surgery
Global Scleritis Market, by End User
- Hospitals & Clinics
- Diagnostic Centers
- Academic & Research Organizations
Request Customization
Get a Sample
Get a Sample
Request Customization